{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:56:32Z","timestamp":1784944592735,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare and analyze the efficacy and safety of different antifungal drug treatment regimens for patients with invasive pulmonary aspergillosis (IPA) in the intensive care unit (ICU).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively collected the clinical data of patients with IPA in the ICU in two grade-A tertiary hospitals from January 2019 to January 2024 using the HIS system and compared the clinical efficacy, incidence of adverse drug reactions (ADRs), and all-cause mortality at discharge among different antifungal treatments, such as voriconazole alone, caspofungin alone, and a combination of voriconazole plus caspofungin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 151 patients were enrolled, including 129 in the monotherapy group (with 92 in the voriconazole subgroup and 37 in the caspofungin subgroup) and 22 in the voriconazole plus caspofungin combination group. <jats:italic>Aspergillus fumigatus<\/jats:italic> was the most common pathogenic fungus in patients with IPA, followed by <jats:italic>Aspergillus flavus<\/jats:italic>. In terms of clinical efficacy, monotherapy and combination therapy were equally effective (<jats:italic>P<\/jats:italic>=0.618), and the efficacy of voriconazole or caspofungin alone and that of voriconazole combined with caspofungin in the treatment of IPA was equivalent (<jats:italic>P<\/jats:italic>=0.630). In terms of safety, the total incidence of ADRs in the combination therapy group was greater than that in the monotherapy group, but the difference was not statistically significant (<jats:italic>P<\/jats:italic>=0.109). The two groups were also equally safe in terms of causing renal dysfunction, liver dysfunction, visual abnormalities, and hypokalemia. However, compared with the monotherapy group, the combination therapy group exhibited a significantly greater incidence of pancytopenia (<jats:italic>P<\/jats:italic>=0.013, <jats:italic>P<\/jats:italic>=0.004). The all-cause mortality in the combination therapy group was significantly greater than that in the monotherapy group (<jats:italic>P<\/jats:italic>=0.027, <jats:italic>P<\/jats:italic>=0.009).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Voriconazole is still the preferred treatment for critically ill patients with IPA, and caspofungin has good clinical efficacy and safety and can effectively replace voriconazole for these patients. However, the combination treatment with voriconazole and caspofungin did not improve the all-cause mortality rate of critically ill patients with IPA, is associated with increased total ADR and pancytopenia incidence and is not recommended as an initial treatment plan.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2025.1584950","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:24:28Z","timestamp":1747805068000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of voriconazole and caspofungin for the treatment of invasive pulmonary aspergillosis in critically ill patients in China"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhuo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/cid\/ciaa1855","article-title":"Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: from the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC\/MSGERC","volume":"72","author":"Alexander","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.idc.2015.10.015","article-title":"Invasive aspergillosis: current strategies for diagnosis and management","volume":"30","author":"Cadena","year":"2016","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1031423","article-title":"Epidemiology and mortality predictors for severe childhood community-acquired pneumonia in ICUs: A retrospective observational study","volume":"11","author":"Cao","year":"2023","journal-title":"Front. Pediatr."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00138-22","article-title":"Relationship between vancomycin trough serum concentrations and clinical outcomes in children: a systematic review and meta-analysis","volume":"66","author":"Cao","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11684-017-0601-0","article-title":"Epidemiology of fungal infections in China","volume":"12","author":"Chen","year":"2018","journal-title":"Front. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3760\/j.issn:0578-1426.2007.11.031","article-title":"Guidelines for the diagnosis and treatment of invasive fungal infections in critically ill patients","volume":"46","year":"2007","journal-title":"Chin. J. Intern. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.ijid.2011.10.004","article-title":"The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review","volume":"16","author":"Garbati","year":"2012","journal-title":"Int. J. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/crj.13585","article-title":"Aspergillus infection in chronic obstructive pulmonary diseases","volume":"17","author":"Guo","year":"2023","journal-title":"Clin. Respir. J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.7539\/j.issn.1672-2981.2020.07.026","article-title":"Research progress of voriconazole combined with amphotericin B in the treatment of invasive pulmonary aspergillosis","volume":"18","author":"Han","year":"2020","journal-title":"Cent. Sou. Pharm."},{"key":"B11","first-page":"2973","article-title":"Significance of Aspergillus spp. isolation from lower respiratory tract samples for the diagnosis and prognosis of invasive pulmonary aspergillosis in chronic obstructive pulmonary disease","volume":"125","author":"He","year":"2012","journal-title":"Chin. Med. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.idc.2025.01.002","article-title":"Invasive aspergillosis in the current era","author":"Herrera","year":"2025","journal-title":"Infect. Dis. Clin. North. Am"},{"key":"B14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3969\/j.issn.1672-3384.2017.02.016","article-title":"Clinical efficacy and safety of caspofungin in the treatment of invasive fungal infections in patients with leukemia undergoing chemotherapy","volume":"15","author":"Hou","year":"2017","journal-title":"J. Clin. Drug Ther."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/20499361241252537","article-title":"Distribution of Aspergillus species and risk factors for aspergillosis in mainland China: a systematic review","volume":"11","author":"Khan","year":"2024","journal-title":"Ther. Adv. Infect. Dis."},{"key":"B16","first-page":"98","article-title":"Microbiological examination and clinical diagnosis and treatment of patients with pulmonary aspergillus infection","volume":"4","author":"Lei","year":"2020","journal-title":"Mod. Med. Hea. R."},{"key":"B17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.cmi.2018.11.027","article-title":"Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management","volume":"25","author":"Lestrade","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"B18","volume-title":"Meta-analysis of the efficacy and safety of caspofungin in the treatment of invasive fungal infections","author":"Li","year":"2015"},{"key":"B19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.15887\/j.cnki.13-1389\/r.2021.06.011","article-title":"Clinical efficacy and safety of voriconazole in the treatment of pulmonary invasive fungal infections","volume":"14","author":"Li","year":"2021","journal-title":"J. CRDU."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/03000605241237878","article-title":"Efficacy and safety of caspofungin for the treatment of invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease","volume":"52","author":"Li","year":"2024","journal-title":"J. Int. Med. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.18093\/0869-0189-2011-0-3-9-52","article-title":"Treatment of fungal infections in adult pulmonary and critical care patients","volume":"3","author":"Limper","year":"2011","journal-title":"Rus. Pulmon."},{"key":"B22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.13201\/j.issn.1009-5918.2017.08.015","article-title":"Characteristics and drug resistance analysis of invasive fungal flora in emergency intensive care unit from 2013 to 2017","volume":"18","author":"Liu","year":"2017","journal-title":"J. Clin. Emerg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.13699\/j.cnki.1001-6821.2018.13.025","article-title":"Analysis of adverse drug reactions of caspofungin","volume":"34","author":"Liu","year":"2018","journal-title":"Chin. J. Clin. Pharma."},{"key":"B24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1186\/s12879-019-4303-x","article-title":"Prospective study of the serum Aspergillus-specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis","volume":"19","author":"Ma","year":"2019","journal-title":"BMC. Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/s0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/m13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ijid.2014.07.007","article-title":"Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis","volume":"28","author":"Panackal","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of america","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41429-021-00460-z","article-title":"Correction: Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011\u20132019)","volume":"75","author":"Pfaller","year":"2022","journal-title":"J. Antibiot."},{"key":"B30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.riam.2013.10.001","article-title":"Epidemiology of candidaemia and invasive candidiasis. A changing face","volume":"31","author":"Quind\u00f3s","year":"2014","journal-title":"Rev. Iberoam. Micol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/jof5020041","article-title":"Antifungal resistance in clinical isolates of Aspergillus spp.: when local epidemiology breaks the norm","volume":"5","author":"Romero","year":"2019","journal-title":"J. Fungi."},{"key":"B32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12890-022-01836-z","article-title":"Outcomes of surgery for different types of chronic pulmonary aspergillosis: results from a single-center, retrospective cohort study","volume":"22","author":"Shen","year":"2022","journal-title":"BMC. Pulm. Med."},{"key":"B33","first-page":"217","article-title":"Retrospective analysis of the data of 1935 clinical isolates of deep Aspergillus","volume":"14","author":"Su","year":"2019","journal-title":"Chin. J. Myco"},{"key":"B34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.13461\/j.cnki.wna.005329","article-title":"Literature analysis of antifungal adverse drug reactions","volume":"41","author":"Tang","year":"2020","journal-title":"For. Med. J. (Antibiot. Sect.)."},{"key":"B35","first-page":"1648","article-title":"Diagnosis and treatment of a patient with invasive pulmonary aspergillosis","volume":"40","author":"Tian","year":"2020","journal-title":"Int. J. Respir. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.rmed.2013.03.016","article-title":"Airway and parenchymal manifestations of pulmonary aspergillosis","volume":"107","author":"Tunnicliffe","year":"2013","journal-title":"Respir. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B40","volume-title":"Risk factors and survival analysis of severe invasive pulmonary aspergillosis","author":"Wang","year":"2022"},{"key":"B41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12890-019-1022-4","article-title":"Metagenomic next-generation sequencing for mixed pulmonary infection diagnosis","volume":"19","author":"Wang","year":"2019","journal-title":"BMC. Pulm. Med."},{"key":"B42","first-page":"65","article-title":"Case analysis of voriconazole combined with caspofungin in the treatment of invasive pulmonary aspergillosis","volume":"17","author":"Wang","year":"2019","journal-title":"Chin. Pres. Drugs"},{"key":"B43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.15887\/j.cnki.13-1389\/r.2021.05.015","article-title":"Pharmaceutical care of a child with pulmonary Nocardia infectious abscess treated clinically","volume":"14","author":"Wang","year":"2021","journal-title":"J. CRDU."},{"key":"B44","doi-asserted-by":"publisher","first-page":"532","DOI":"10.12138\/j.issn.1671-9638.20216690","article-title":"Preliminary clinical experience of antifungal drug combination therapy for invasive pulmonary aspergillosis in critically ill ICU patients","volume":"20","author":"Yang","year":"2021","journal-title":"Chin. J. Infect. Cont"},{"key":"B45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.14164\/j.cnki.cn11-5581\/r.2023.09.035","article-title":"Exploration of the efficacy and safety of caspofungin combined with other antifungal drugs in the treatment of neutropenia complicated with invasive fungal infection in patients with Malignant hematological diseases","volume":"17","author":"Yang","year":"2013","journal-title":"Chin. J. Modern. Drug App."},{"key":"B46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2741\/s477","article-title":"The emergence of Aspergillus species in chronic respiratory disease","volume":"9","author":"Yii","year":"2017","journal-title":"Front. Biosci (Schol Ed)."},{"key":"B47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12072-017-9793-2","article-title":"Guidelines for the diagnosis and treatment of drug-induced liver injury","volume":"220","author":"Yu","year":"2017","journal-title":"Prac. J. Liver. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2147\/idr.S497840","article-title":"Predictors for invasive pulmonary aspergillosis in acute-on-chronic liver failure patients: A retrospective study","volume":"18","author":"Yuan","year":"2025","journal-title":"Infect. Drug Resist."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.3969\/ji.ssn.1673-4130.2023.23.024","article-title":"A comparative study on the identification results of aspergillus by three methods","volume":"44","author":"Zhang","year":"2023","journal-title":"Int. J. Lab. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3969\/j.issn.0253-9926.2019.16.025","article-title":"Clinical study of voriconazole in the treatment of 58 cases of chronic obstructive pulmonary disease with invasive pulmonary aspergillus","volume":"48","author":"Zhang","year":"2019","journal-title":"Shanxi. Med. J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.19435\/j.1672-1721.2018.31.046","article-title":"Discussion on the efficacy and safety of different antifungal drugs in the treatment of invasive pulmonary aspergillosis","volume":"22","author":"Zheng","year":"2018","journal-title":"Prim. Med. Forum"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1584950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:24:41Z","timestamp":1747805081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1584950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":51,"alternative-id":["10.3389\/fcimb.2025.1584950"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1584950","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1584950"}}